Pulling SEC filings + quote and writing the call…

Ares Management Corp
Next earnings Jul 30, 2026 (before open) · consensus $1.36 EPS, $1.26B rev
Last earnings +1.4% on 2026-05-01
Sticky, long-dated fee streams and 44% revenue growth at ~20x earnings make ARES a quality compounder at a fair price.
Revenue (FY2025) $5.60B · FY2025
Ares is a durable, fee-engine alternative asset manager, and the MD&A makes the quality visible: management fees are charged on capital commitments, invested capital and NAV across credit, real assets, secondaries and private equity, with average remaining contract terms running 3–9 years (8.1 years in secondaries, 9.3 in liquid credit, 5.5 in direct lending). That is contracted, recurring revenue that does not reset with market marks — the most valuable kind of asset-manager income. FY2025 revenue grew +44.2% to $5.60B and operating cash flow reached $3.27B, more than 6x reported net income, confirming the fee base converts to cash even though much of the GAAP economics flows to non-controlling interests under the Up-C structure (which is why net margin reads a thin 9.4%).
On the provided figures the valuation is undemanding for this quality: P/S of 1.9 and an implied P/E near 20x ($10.7B cap on $527M net income) for a business growing fees double-digits with multi-year contractual visibility. Net income rose +13.7% and equity +20.7%, while the perpetual wealth vehicles (sales- and asset-based fees on NAV) add a structurally growing distribution channel called out in the filing. For a long-horizon owner, that combination — recurring fee growth, strong cash generation, reasonable multiple — is the case for buying.
Is ARES a buy? The one-page verdict, explained →
BUY verdict with defined risk: the short call finances part of the long one; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $4.21B | $3.06B | $3.63B | $3.88B | $5.60B |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $409M | $168M | $474M | $464M | $527M |
| Diluted EPS | — | — | — | — | — |
| Net margin | 9.7% | 5.5% | 13.1% | 11.9% | 9.4% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting results: directors elected, auditor ratified, say-on-pay approved
Entered new material agreement creating direct financial obligation (new debt)
Q1 FY26 10-Q: AUM and fee-related growth sustain top-line momentum
Q1 2026 earnings released; fee-related revenue momentum continues
2026 proxy: board slate, exec comp and say-on-pay up for shareholder vote
New material agreement creating direct financial obligation (debt issuance)
New material agreement creating direct financial obligation (debt issuance)
FY2025 10-K: revenue +44% to $5.6B, NI +14%, equity +21%; leverage 4.7x
FY2025/Q4 earnings: revenue surged 44% YoY to $5.6B, net income +14%
Sources: SEC EDGAR (CIK 0001176948, latest 10-Q filed 2026-05-08) · EODHD · Proprietary analysis · as of 6/21/2026, 4:27:19 PM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 12:27 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2026-07-01 | Phillips Jarrod Chief Financial Officer | Tax | 2.58K @ $113.63 | $294K |
| 2026-06-30 | Arougheti Michael J Co-Founder and CEO | Tax | 83.0K @ $111.31 | $9.23M |
| 2026-06-30 | deVeer R. Kipp Co-President | Tax | 83.0K @ $111.31 | $9.23M |
| 2026-06-03 | Jacobson Blair Co-President | Gift | 8.00K | |
| 2026-02-20 | Olian Judy D. Director | Buy | 480.00 @ $124.43 | $59.7K |
| 2026-02-06 | BHUTANI ASHISH Director | Buy | 10.0K @ $126.61 | $1.27M |
| 2026-02-04 | Sagati Aghili Naseem General Counsel | Sell | 300.00 @ $126.68 | $38.0K |
| 2026-02-04 | Sagati Aghili Naseem General Counsel | Sell | 300.00 @ $128.98 | $38.7K |
| 2026-02-04 | Sagati Aghili Naseem General Counsel | Sell | 100.00 @ $131.61 | $13.2K |
| 2026-02-04 | Sagati Aghili Naseem General Counsel | Sell | 300.00 @ $134.00 | $40.2K |
| 2026-02-04 | Sagati Aghili Naseem General Counsel | Sell | 1.11K @ $135.28 | $150K |
| 2026-02-04 | Sagati Aghili Naseem General Counsel | Sell | 611.00 @ $136.74 | $83.5K |
| Citadel Advisors | 2.08M sh | $227M |
| Point72 Asset Management | 1.29M sh | $141M |
| Millennium Management | 1.17M sh | $128M |
| Soros Fund Management | 196K sh | $21.4M |
As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.